Immunotherapy of multifocal motor neuropathy

Bibliography

• van Schaik IN, Bouche P, Illa I, EFNS/PNS guideline on management of multifocal motor neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. Eur J Neurol 2006;13:802-8
   PubMed Web of Science ®Google Scholar
• Cats EA, van der Pol WL, Piepers S, Correlates of outcome and response to IVIg in 88 patients with multifocal motor neuropathy. Neurology 2010;75:818-25
   PubMed Web of Science ®Google Scholar
• Nobile-Orazio E. Multifocal motor neuropathy. J Neuroimmunol 2001;115:4-18
   PubMed Web of Science ®Google Scholar
• Slee M, Selvan A, Donaghy M. Multifocal motor neuropathy: the diagnostic spectrum and response to treatment. Neurology 2007;69:1680-7
   PubMed Web of Science ®Google Scholar
• Van Asseldonk JTH, Franssen H, Van den Berg-Vos RM, Multifocal motor neuropathy. Lancet Neurol 2005;4:309-19
   PubMed Web of Science ®Google Scholar
• Roth G, Rohr J, Magistris MR, Ochsner F. Motor neuropathy with proximal multifocal persistent conduction block, fasciculations and myokymia. Evolution to tetraplegia. Eur Neurol 1986;25:416-23
   PubMed Web of Science ®Google Scholar
• Chad DA, Hammer K, Sargent J. Slow resolution of multifocal weakness and fasciculation: a reversible motor neuron syndrome. Neurology 1986;36:1260-3
   PubMed Web of Science ®Google Scholar
• Pestronk A, Cornblath DR, Ilyas AA, A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside. Ann Neurol 1988;24:73-8
   PubMed Web of Science ®Google Scholar
• Parry GJ, Clarke S. Multifocal acquired demyelinating neuropathy masquerading as motor neuron disease. Muscle Nerve 1988;11:103-7
   PubMed Web of Science ®Google Scholar
• Willison HJ, Veitch J, Swan AV, Inter-laboratory validation of an ELISA for the determination of serum anti-ganglioside antibodies. Eur J Neurol 1999;6:71-7
   PubMed Web of Science ®Google Scholar
• Eftimov F, Lunn MPT, Leeflang MMG, van Schaik IN. Anti-GM1 antibody testing for multifocal motor neuropathy (Protocol). Cochrane Database Syst Rev 2010:CD008595
   Google Scholar
• Van Es HW, Van den Berg LH, Franssen H, Magnetic resonance imaging of the brachial plexus in patients with multifocal motor neuropathy. Neurology 1997;48:1218-24
   PubMed Web of Science ®Google Scholar
• Lambrecq V, Krim E, Rouanet-Larriviere M, Lagueny A. Sensory loss in multifocal motor neuropathy: a clinical and electrophysiological study. Muscle Nerve 2009;39:131-6
   PubMed Web of Science ®Google Scholar
• Adams D, Kuntzer T, Steck AJ, Motor conduction block and high titres of anti-GM1 ganglioside antibodies: pathological evidence of a motor neuropathy in a patient with lower motor neuron syndrome. J Neurol Neurosurg Psychiatry 1993;56:982-7
   PubMed Web of Science ®Google Scholar
• Paparounas K, O'Hanlon GM, O'Leary CP, Anti-ganglioside antibodies can bind peripheral nerve nodes of Ranvier and activate the complement cascade without inducing acute conduction block in vitro. Brain 1999;122(Pt 5):807-16
   PubMed Web of Science ®Google Scholar
• Yuki N, Watanabe H, Nakajima T, Spath PJ. IVIG blocks complement deposition mediated by anti-GM1 antibodies in multifocal motor neuropathy. J Neurol Neurosurg Psychiatry 2011;82:87-91
   PubMed Web of Science ®Google Scholar
• Arasaki K, Kusunoki S, Kudo N, Kanazawa I. Acute conduction block in vitro following exposure to antiganglioside sera. Muscle Nerve 1993;16:587-93
   PubMed Web of Science ®Google Scholar
• Santoro M, Uncini A, Corbo M, Experimental conduction block induced by serum from a patient with anti-GM1 antibodies. Ann Neurol 1992;31:385-90
   PubMed Web of Science ®Google Scholar
• Nobile-Orazio E, Giannotta C, Briani C. Anti-ganglioside complex IgM antibodies in multifocal motor neuropathy and chronic immune-mediated neuropathies. J Neuroimmunol 2010;219:119-22
   PubMed Web of Science ®Google Scholar
• Greenshields KN, Halstead SK, Zitman FM, The neuropathic potential of anti-GM1 autoantibodies is regulated by the local glycolipid environment in mice. J Clin Invest 2009;119:595-610
   PubMed Web of Science ®Google Scholar
• Jacob S, Rajabally YA. Current proposed mechanisms of action of intravenous immunoglobulins in inflammatory neuropathies. Curr Neuropharmacol 2009;7:337-42
   PubMed Web of Science ®Google Scholar
• Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001;345:747-55
   PubMed Web of Science ®Google Scholar
• Dalakas MC. Mechanisms of action of IVIg and therapeutic considerations in the treatment of acute and chronic demyelinating neuropathies. Neurology 2002;59:S13-21
   PubMed Web of Science ®Google Scholar
• van Schaik IN, Vermeulen M, Brand A. In vitro effects of polyvalent immunoglobulin for intravenous use. J Neurol Neurosurg Psychiatry 1994;57(Suppl):15-7
   PubMed Web of Science ®Google Scholar
• van Schaik IN, Lundkvist I, Vermeulen M, Brand A. Polyvalent immunoglobulin for intravenous use interferes with cell proliferation in vitro. J Clin Immunol 1992;12:325-34
   PubMed Web of Science ®Google Scholar
• Misra N, Bayary J, Dasgupta S, Intravenous immunoglobulin and dendritic cells. Clin Rev Allergy Immunol 2005;29:201-5
   PubMed Web of Science ®Google Scholar
• van Schaik IN, Vermeulen M, Brand A. Immunomodulation and remyelination: two aspects of human polyclonal immunoglobulin treatment in immune mediated neuropathies? Mult Scler 1997;3:98-104
   PubMed Web of Science ®Google Scholar
• Kaji R, Shibasaki H, Kimura J. Multifocal demyelinating motor neuropathy: cranial nerve involvement and immunoglobulin therapy. Neurology 1992;42:506-9
   PubMed Web of Science ®Google Scholar
• Charles N, Benoit P, Vial C, Intravenous immunoglobulin treatment in multifocal motor neuropathy. Lancet 1992;340:182
   PubMed Web of Science ®Google Scholar
• Kermode AG, Laing BA, Carroll WM, Mastaglia FL. Intravenous immunoglobulin for multifocal motor neuropathy. Lancet 1992;340:920-1
   PubMed Web of Science ®Google Scholar
• Van Doorn PA, Brand A, Strengers PFW, High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, crossover study. Neurology 1990;40:209-12
   PubMed Web of Science ®Google Scholar
• Chaudhry V, Corse AM, Cornblath DR, Multifocal motor neuropathy: response to human immune globulin. Ann Neurol 1993;33:237-42
   PubMed Web of Science ®Google Scholar
• Azulay JP, Blin O, Pouget J, Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: a double-blind, placebo-controlled study. Neurology 1994;44:429-32
   PubMed Web of Science ®Google Scholar
• Van den Berg LH, Kerkhoff H, Oey PL, Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 1995;59:248-52
   PubMed Web of Science ®Google Scholar
• Federico P, Zochodne DW, Hahn AF, Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebo-controlled study. Neurology 2000;55:1256-62
   PubMed Web of Science ®Google Scholar
• Leger JM, Chassande B, Musset L, Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study. Brain 2001;124:145-53
   PubMed Web of Science ®Google Scholar
• van Schaik IN, Van den Berg LH, de Haan R, Vermeulen M. Intravenous immunoglobulin for multifocal motor neuropathy. Cochrane Database Syst Rev 2005:CD004429
   Google Scholar
• Leger JM, Viala K, Cancalon F, Intravenous immunoglobulin as short- and long-term therapy of multifocal motor neuropathy: a retrospective study of response to IVIg and of its predictive criteria in 40 patients. J Neurol Neurosurg Psychiatry 2008;79:93-6
   PubMed Web of Science ®Google Scholar
• Delmont E, Azulay JP, Giorgi R, Multifocal motor neuropathy with and without conduction block: a single entity? Neurology 2006;67:592-6
   PubMed Web of Science ®Google Scholar
• Van Asseldonk JTH, Van den Berg LH, Kalmijn S, Axonal loss is an important determinant of weakness in multifocal motor neuropathy. J Neurol Neurosurg Psychiatry 2006;77:743-7
   PubMed Web of Science ®Google Scholar
• Van den Berg-Vos RM, Franssen H, Wokke JHJ, Van den Berg LH. Multifocal motor neuropathy: long-term clinical and electrophysiological assessment of intravenous immunoglobulin maintenance treatment. Brain 2002;125:1875-86
   PubMed Web of Science ®Google Scholar
• Terenghi F, Cappellari A, Bersano A, How long is IVIg effective in multifocal motor neuropathy? Neurology 2004;62:666-8
   PubMed Web of Science ®Google Scholar
• Vucic S, Black KR, Chong PST, Cros D. Multifocal motor neuropathy. Decrease in conduction blocks and reinnervation with long-term IVIg. Neurology 2004;63:1264-9
   PubMed Web of Science ®Google Scholar
• Baumann A, Hess CW, Sturzenegger M. IVIg dose increase in multifocal motor neuropathy: a prospective six month follow-up. J Neurol 2009;256:608-14
   PubMed Web of Science ®Google Scholar
• Nobile-Orazio E, Cappellari A, Meucci N, Multifocal motor neuropathy: clinical and immunological features and response to IVIg in relation to the presence and degree of motor conduction block. J Neurol Neurosurg Psychiatry 2002;72:761-6
   PubMed Web of Science ®Google Scholar
• Azulay JP, Rihet P, Pouget J, Long term follow up of multifocal motor neuropathy with conduction block under treatment. J Neurol Neurosurg Psychiatry 1997;62:391-4
   PubMed Web of Science ®Google Scholar
• Sekul EA, Cupler EJ, Dalakas MC. Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors. Ann Intern Med 1994;121:259-62
   PubMed Web of Science ®Google Scholar
• Debes A, Bauer M, Kremer S. Tolerability and safety of the intravenous immunoglobulin Octagam: a 10-year prospective observational study. Pharmacoepidemiol Drug Saf 2007;16:1038-47
   PubMed Web of Science ®Google Scholar
• Nydegger UE, Sturzenegger M. Adverse effects of intravenous immunoglobulin therapy. Drug Saf 1999;21:171-85
   PubMed Web of Science ®Google Scholar
• Caress JB, Hobson-Webb L, Passmore LV, Case-control study of thromboembolic events associated with IV immunoglobulin. J Neurol 2009;256:339-42
   PubMed Web of Science ®Google Scholar
• Chen C, Danekas LH, Ratko TA, A multicenter drug use surveillance of intravenous immunoglobulin utilization in US academic health centers. Ann Pharmacother 2000;34:295-9
   PubMed Web of Science ®Google Scholar
• Koller H, Schroeter M, Feischen H, Subcutaneous self-infusions of immunoglobulins as a potential therapeutic regimen in immune-mediated neuropathies. J Neurol 2006;253:1505-6
   PubMed Web of Science ®Google Scholar
• Lee DH, Linker RA, Paulus W, Subcutaneous immunoglobulin infusion: a new therapeutic option in chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 2008;37:406-9
   PubMed Web of Science ®Google Scholar
• Harbo T, Andersen H, Hess A, Subcutaneous versus intravenous immunoglobulin in multifocal motor neuropathy: a randomized, single-blinded cross-over trial. Eur J Neurol 2009;16:631-8
   PubMed Web of Science ®Google Scholar
• Harbo T, Andersen H, Jakobsen J. Long-term therapy with high doses of subcutaneous immunoglobulin in multifocal motor neuropathy. Neurology 2010;75:1377-80
   PubMed Web of Science ®Google Scholar
• Eftimov F, Vermeulen M, de Haan RJ, Subcutaneous immunoglobulin therapy for multifocal motor neuropathy. J Peripher Nerv Syst 2009;14:93-100
   PubMed Web of Science ®Google Scholar
• Gardulf A, Nicolay U, Math D, Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home. J Allergy Clin Immunol 2004;114:936-42
   PubMed Web of Science ®Google Scholar
• Czock D, Keller F, Rasche FM, Haussler U. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet 2005;44:61-98
   PubMed Web of Science ®Google Scholar
• Krarup C, Stewart JD, Sumner AJ, A syndrome of asymmetric limb weakness with motor conduction block. Neurology 1990;40:118-27
   PubMed Web of Science ®Google Scholar
• Feldman EL, Bromberg MB, Albers JW, Pestronk A. Immunosuppressive treatment in multifocal motor neuropathy. Ann Neurol 1991;30:397-401
   PubMed Web of Science ®Google Scholar
• Tan E, Lynn DJ, Amato AA, Immunosuppressive treatment of motor neuron syndromes. Attempts to distinguish a treatable disorder. Arch Neurol 1994;51:194-200
   PubMed Web of Science ®Google Scholar
• Nobile-Orazio E, Meucci N, Barbieri S, High-dose intravenous immunoglobulin therapy in multifocal motor neuropathy. Neurology 1993;43:537-44
   PubMed Web of Science ®Google Scholar
• Donaghy M, Mills KR, Boniface SJ, Pure motor demyelinating neuropathy: deterioration after steroid treatment and improvement with intravenous immunoglobulin. J Neurol Neurosurg Psychiatry 1994;57:778-83
   PubMed Web of Science ®Google Scholar
• Van den Berg LH, Lokhorst H, Wokke JH. Pulsed high-dose dexamethasone is not effective in patients with multifocal motor neuropathy. Neurology 1997;48:1135
   PubMed Web of Science ®Google Scholar
• Umapathi T, Hughes RAC, Nobile-Orazio E, Leger JM. Immunosuppressant and immunomodulatory treatments for multifocal motor neuropathy. Cochrane Database Syst Rev 2009;(1):CD003217
   Google Scholar
• Lehmann HC, Hoffmann FR, Fusshoeller A, The clinical value of therapeutic plasma exchange in multifocal motor neuropathy. J Neurol Sci 2008;271:34-9
   PubMed Web of Science ®Google Scholar
• Beydoun SR. Multifocal motor neuropathy with conduction block misdiagnosed as multiple entrapment neuropathies. Muscle Nerve 1998;21:813-15
   PubMed Web of Science ®Google Scholar
• Beydoun SR, Copeland D. Bilateral phrenic neuropathy as a presenting feature of multifocal motor neuropathy with conduction block. Muscle Nerve 2000;23:556-9
   PubMed Web of Science ®Google Scholar
• Carpo M, Cappellari A, Mora G, Deterioration of multifocal motor neuropathy after plasma exchange. Neurology 1998;50:1480-2
   PubMed Web of Science ®Google Scholar
• Claus D, Specht S, Zieschang M. Plasmapheresis in multifocal motor neuropathy: a case report. J Neurol Neurosurg Psychiatry 2000;68:533-5
   PubMed Web of Science ®Google Scholar
• Finsterer J, Derfler K. Immunoadsorption in multifocal motor neuropathy. J Immunother 1999;22:441-2
   PubMed Web of Science ®Google Scholar
• Kiprov DD, Golden P, Rohe R, Adverse reactions associated with mobile therapeutic apheresis: analysis of 17,940 procedures. J Clin Apher 2001;16:130-3
   PubMed Web of Science ®Google Scholar
• Norda R, Stegmayr BG. Therapeutic apheresis in Sweden: update of epidemiology and adverse events. Transfus Apher Sci 2003;29:159-66
   PubMed Web of Science ®Google Scholar
• Pringle CE, Belden J, Veitch JE, Brown WF. Multifocal motor neuropathy presenting as ophthalmoplegia. Muscle Nerve 1997;20:347-51
   PubMed Web of Science ®Google Scholar
• Estrada-Acosta R, Lestayo-O'Farrill Z, Coba-Morales C. Multifocal motor neuropathy with block of nerve conduction. Report of three cases. Rev Neurol 1999;29:130-3
   PubMed Web of Science ®Google Scholar
• Branagan TH, Alaedini A, Gladstone DE. High-dose cyclophosphamide without stem cell rescue for refractory mutlifocal motor neuropathy. Muscle Nerve 2006;34:246-50
   PubMed Web of Science ®Google Scholar
• Axelson HW, Oberg G, Askmark H. No benefit of treatment with cyclophosphamide and autologous blood stem cell transplantation in multifocal motor neuropathy. Acta Neurol Scand 2008;117:432-4
   PubMed Web of Science ®Google Scholar
• Meucci N, Cappellari A, Barbieri S, Long term effect of intravenous immunoglobulins and oral cyclophosphamide in multifocal motor neuropathy. J Neurol Neurosurg Psychiatry 1997;63:765-9
   PubMed Web of Science ®Google Scholar
• Piepers S, Berg-Vos R, van der Pol WL, Mycophenolate mofetil as adjunctive therapy for MMN patients: a randomized, controlled trial. Brain 2007;130:2004-10
   PubMed Web of Science ®Google Scholar
• Benedetti L, Grandis M, Nobbio L, Mycophenolate mofetil in dysimmune neuropathies: a preliminary study. Muscle Nerve 2004;29:748-9
   PubMed Web of Science ®Google Scholar
• Umapathi T, Hughes RAC. Mycophenolate in treatment-resistant inflammatory neuropathies. Eur J Neurol 2002;9:683-5
   PubMed Web of Science ®Google Scholar
• Pestronk A, Florence J, Miller T, Treatment of IgM antibody associated polyneuropathies using rituximab. J Neurol Neurosurg Psychiatry 2003;74:485-9
   PubMed Web of Science ®Google Scholar
• Rojas-Garcia R, Gallardo E, de Andres I, Chronic neuropathy with IgM anti-ganglioside antibodies: Lack of long term response to rituximab. Neurology 2003;61:1814-16
   PubMed Web of Science ®Google Scholar
• Stieglbauer K, Topakian R, Hinterberger G, Aichner FT. Beneficial effect of rituximab monotherapy in multifocal motor neuropathy. Neuromuscul Disord 2009;19:473-5
   PubMed Web of Science ®Google Scholar
• Ruegg SJ, Fuhr P, Steck AJ. Rituximab stabilizes multifocal motor neuropathy increasingly less responsive to IVIg. Neurology 2004;63:2178-9
   PubMed Web of Science ®Google Scholar
• Gorson KC, Natarajan N, Ropper AH, Weinstein R. Rituximab treatment in patients with IVIg-dependent immune polyneuropathy: a prospective pilot trial. Muscle Nerve 2007;35:66-9
   PubMed Web of Science ®Google Scholar
• Chaudhry V, Cornblath DR. An open-label trial of rituximab (Rituxan®) in multifocal motor neuropathy. J Peripher Nerv Syst 2010;15:196-201
   PubMed Web of Science ®Google Scholar
• Carson KR, Evens AM, Richey EA, Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009;113:4834-40
   PubMed Web of Science ®Google Scholar
• Nobile-Orazio E, Terenghi F, Cocito D, Oral methotrexate as adjunctive therapy in patients with multifocal motor neuropathy on chronic IVIg therapy. J Peripher Nerv Syst 2009;14:203-5
   PubMed Web of Science ®Google Scholar
• Hausmanowa-Petrusewicz I, Rowinska-Marcinska K, Kopec A. Chronic acquired demyelinating motor neuropathy. Acta Neurol Scand 1991;84:40-5
   PubMed Web of Science ®Google Scholar
• Bouche P, Moulonguet A, Younes-Chennoufi AB, Multifocal motor neuropathy with conduction block: a study of 24 patients. J Neurol Neurosurg Psychiatry 1995;59:38-44
   PubMed Web of Science ®Google Scholar
• Toscano A, Rodolico C, Benvenga S, Multifocal motor neuropathy and asymptomatic Hashimoto's thyroiditis: first report of an association. Neuromuscul Disord 2002;12:566-8
   PubMed Web of Science ®Google Scholar
• Gutierrez Ronquillo JH, Andrade MR, Machado RA, Garcia EA. Multifocal motor neuropathy with partial block of nerve conduction. Rev Neurol 2001;32:427-30
   PubMed Web of Science ®Google Scholar
• Nemni R, Santuccio G, Calabrese E, Efficacy of cyclosporine treatment in multifocal motor neuropathy. J Neurol 2003;250:1118-20
   PubMed Web of Science ®Google Scholar
• Rice GP, Incorvaia B, Munari L, Interferon in relapsing-remitting multiple sclerosis. Cochrane Database Syst Rev 2001:CD002002
   Google Scholar
• Martina IS, Van Doorn PA, Schmitz PI, Chronic motor neuropathies: response to interferon-beta1a after failure of conventional therapies. J Neurol Neurosurg Psychiatry 1999;66:197-201
   PubMed Web of Science ®Google Scholar
• Van den Berg-Vos RM, Van den Berg LH, Franssen H, Treatment of multifocal motor neuropathy with interferon-beta1A. Neurology 2000;54:1518-21
   PubMed Web of Science ®Google Scholar
• Radziwill AJ, Botez SA, Novy J, Kuntzer T. Interferon beta-1a as adjunctive treatment for multifocal motor neuropathy: an open label trial. J Peripher Nerv Syst 2009;14:201-2
   PubMed Web of Science ®Google Scholar
• Cocito D, Bergamasco B, Tavella A, Multifocal motor neuropathy during treatment with infliximab. J Peripher Nerv Syst 2005;10:386-7
   PubMed Web of Science ®Google Scholar
• Lozeron P, Denier C, Lacroix C, Adams D. Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-alpha-blocker therapy. Arch Neurol 2009;66:490-7
   PubMed Web of Science ®Google Scholar
• Barber CE, Lee P, Steinhart AH, Lazarou J. Multifocal motor neuropathy with conduction block following treatment with infliximab. J Rheumatol 2010;37:1778-80
   PubMed Web of Science ®Google Scholar
• Rodriguez-Escalera C, Belzunegui J, Lopez-Dominguez L, Multifocal motor neuropathy with conduction block in a patient with rheumatoid arthritis on infliximab therapy. Rheumatology (Oxford) 2005;44:132-3
   PubMed Web of Science ®Google Scholar
• Paolazzi G, Peccatori S, Cavatorta FP, Morini A. A case of spontaneously recovering multifocal motor neuropathy with conduction blocks (MMNCB) during anti-TNF alpha therapy for ankylosing spondylitis. Clin Rheumatol 2009;28:993-5
   PubMed Web of Science ®Google Scholar
• Kuitwaard K, van den Berg LH, Vermeulen M, Randomised controlled trial comparing two different intravenous immunoglobulins in chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol Neurosurg Psychiatry 2010;81:1374-9
   PubMed Web of Science ®Google Scholar
• RMC Trial Group. Randomised controlled trial of methotrexate for chronic inflammatory demyelinating polyradiculoneuropathy (RMC trial): a pilot, multicentre study. Lancet Neurol 2009;8:158-64
   PubMed Web of Science ®Google Scholar
• Baxter Healthcare Corporation. A Randomized, Double-Blind, Placebo Controlled, Cross-over Study of the Effectiveness of Immune Globulin Intravenous (Human), 10% (IGIV, 10%) for the treatment of multifocal motor neuropathy. clinicaltrials.gov; NCT00666263
   Google Scholar
• Misbah S, Comi G, Fazio R, Efficacy and safety of subcutaneous immunoglobulin, Vivaglobin, in patients with multifocal motor neuropathy. J Neurol 2010;257(Suppl 1):S105-6
   Google Scholar